SCHEMBL719010

SCHEMBL719010

CCCCC1=NS(=O)(=O)c2ccc(Cl)cc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 7/20 0.47
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
THRB P10828 3/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2D6 P10635 2/20 0.47
TSHR P16473 2/20 0.47
CYP1A2 P05177 2/20 0.47
HTR1A P08908 1/20 0.47
ABCC8 Q09428 1/20 0.47
KCNJ11 Q14654 1/20 0.47
MAPT P10636 3/20 0.44
TP53 P04637 2/20 0.44
MAPK1 P28482 1/20 0.44
RECQL P46063 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP2C9 P11712 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721277 0.96 NPC1 (0.47) NPC1ALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7951206 0.77 CYP1A2 (0.44) NPC1ALDH1A1LMNASMN1; SMN2THRB
SCHEMBL5624731 0.77 HTR1A (0.48) NPC1ALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7944207 0.76 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2THRBCYP3A4
SCHEMBL7944026 0.76 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2THRBCYP3A4
SCHEMBL8492228 0.75 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2THRBCYP3A4
SCHEMBL720640 0.75 ALDH1A1 (0.66) NPC1ALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7950905 0.75 ABCC8 (0.56) ALDH1A1LMNASMN1; SMN2THRBCYP3A4
SCHEMBL7950736 0.75 CYP1A2 (0.47) ALDH1A1LMNASMN1; SMN2THRBCYP3A4
SCHEMBL721585 0.74 ABCC8 (0.79) ALDH1A1LMNASMN1; SMN2THRBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053172-A1 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS COOPERATIEVE MIRZORG U.A. 2012-03-01 US disclosed
US-20100234362-A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL COOPERATIEVE MIRZORG U.A. (NL) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053172-A1 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS GPR119, KCNJ1, GLP1R NPC1 797/4885ALDH1A1 1266/4885LMNA 932/4885
US-20100234362-A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL KCNN4, KCNN1, GPR119 NPC1 932/4885ALDH1A1 1627/4885LMNA 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.